6
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T18636 | PROTAC ERα Degrader-1 | Others | |
PROTAC ERα Degrader-1 is a chemical compound. It consists of a ubiquitin E3 ligase binding group, a linker, and a protein binding group. This compound serves as a degrader of estrogen receptor-alpha (ERα). | |||
T74375 | PROTAC ERα Y537S degrader-1 | ||
PROTAC ERα Y537S degrader-1 comprises a ubiquitin E3 ligase binding group, a linker and a protein binding group. PROTAC ERα Y537S degrader-1 is an estrogen receptor-alpha (ERα) Y537S degrader [1] . | |||
T18605 | PROTAC ERα Degrader-2 | Others | |
PROTAC ERα Degrader-2 is composed of a cIAP1 ligand binding group, a linker, and an estrogen receptor α (ERα) binding group, serving as an ERα degrader. It achieves maximal ERα degradation in human mammary tumor MCF7 cel... | |||
T18606 | PROTAC ER Degrader-2 | Others | |
PROTAC ER Degrader-2 serves as a synthesis intermediate for the production of PAC, a compound that incorporates the ADCs linker and PROTACs, which are subsequently conjugated to an antibody. PAC, exhibits a greater capab... | |||
T18607 | PROTAC ER Degrader-3 | Others | |
PROTAC ER Degrader-3, an intermediate for the synthesis of PAC, specifically compound LP2. PAC serves as the linker for ADCs and PROTACs that are conjugated to an antibody. Notably, when PAC is conjugated to an antibody,... | |||
T78824 | ERD-3111 | Estrogen Receptor/ERR | |
ERD-3111 (Compound 44), an orally active PROTAC ERα degrader (DC50: 0.5 nM), exhibits efficacy in inhibiting tumor growth in both the parental MCF-7 xenograft model harboring wild-type ER and two ESR1-mutated mouse model... |